210 related articles for article (PubMed ID: 32510620)
1. Exploration of the molecular characteristics of the tumor-immune interaction and the development of an individualized immune prognostic signature for neuroblastoma.
Jin W; Zhang Y; Liu Z; Che Z; Gao M; Peng H
J Cell Physiol; 2021 Jan; 236(1):294-308. PubMed ID: 32510620
[TBL] [Abstract][Full Text] [Related]
2. Immunological landscape of Neuroblastoma and its clinical significance.
Batchu S
Cancer Treat Res Commun; 2021; 26():100274. PubMed ID: 33338852
[TBL] [Abstract][Full Text] [Related]
3. Establishment and Validation of a Prognostic Immune Signature in Neuroblastoma.
Yu Y; Zeng Y; Xia X; Zhou JG; Cao F
Cancer Control; 2021; 28():10732748211033751. PubMed ID: 34569303
[TBL] [Abstract][Full Text] [Related]
4. A signature based on five immune-related genes to predict the survival and immune characteristics of neuroblastoma.
Ma K; Zhang P; Xia Y; Dong L; Li Y; Liu L; Liu Y; Wang Y
BMC Med Genomics; 2022 Nov; 15(1):242. PubMed ID: 36419120
[TBL] [Abstract][Full Text] [Related]
5. A novel risk signature that combines 10 long noncoding RNAs to predict neuroblastoma prognosis.
Gao L; Lin P; Chen P; Gao RZ; Yang H; He Y; Chen JB; Luo YG; Xu QQ; Liang SW; Gu JH; Huang ZG; Dang YW; Chen G
J Cell Physiol; 2020 Apr; 235(4):3823-3834. PubMed ID: 31612488
[TBL] [Abstract][Full Text] [Related]
6. Identification of an immune gene-associated prognostic signature in patients with bladder cancer.
Wang Z; Zhu L; Li L; Stebbing J; Wang Z; Peng L
Cancer Gene Ther; 2022 May; 29(5):494-504. PubMed ID: 35169299
[TBL] [Abstract][Full Text] [Related]
7. Development of a macrophages-related 4-gene signature and nomogram for the overall survival prediction of hepatocellular carcinoma based on WGCNA and LASSO algorithm.
Yang Z; Zi Q; Xu K; Wang C; Chi Q
Int Immunopharmacol; 2021 Jan; 90():107238. PubMed ID: 33316739
[TBL] [Abstract][Full Text] [Related]
8. Development and Validation of a Five-RNA-Based Signature and Identification of Candidate Drugs for Neuroblastoma.
Zhang P; Ma K; Ke X; Liu L; Li Y; Liu Y; Wang Y
Front Genet; 2021; 12():685646. PubMed ID: 34745201
[TBL] [Abstract][Full Text] [Related]
9. Identification of an Immune Gene-Associated Prognostic Signature and Its Association With a Poor Prognosis in Gastric Cancer Patients.
Guan X; Xu ZY; Chen R; Qin JJ; Cheng XD
Front Oncol; 2020; 10():629909. PubMed ID: 33628738
[TBL] [Abstract][Full Text] [Related]
10. Model for predicting prognosis and immunotherapy based on CD
Bao W; Song Z; Wan H; Yu X; Chen Z; Jiang Y; Chen X; Le K
J Cancer Res Clin Oncol; 2023 Sep; 149(12):9839-9855. PubMed ID: 37248319
[TBL] [Abstract][Full Text] [Related]
11. A transplantable TH-MYCN transgenic tumor model in C57Bl/6 mice for preclinical immunological studies in neuroblastoma.
Kroesen M; Nierkens S; Ansems M; Wassink M; Orentas RJ; Boon L; den Brok MH; Hoogerbrugge PM; Adema GJ
Int J Cancer; 2014 Mar; 134(6):1335-45. PubMed ID: 24038106
[TBL] [Abstract][Full Text] [Related]
12. The immune landscape of solid pediatric tumors.
Sherif S; Roelands J; Mifsud W; Ahmed EI; Raynaud CM; Rinchai D; Sathappan A; Maaz A; Saleh A; Ozer E; Fakhro KA; Mifsud B; Thorsson V; Bedognetti D; Hendrickx WRL
J Exp Clin Cancer Res; 2022 Jun; 41(1):199. PubMed ID: 35690832
[TBL] [Abstract][Full Text] [Related]
13. [Occurrence and prognostic impact of selected factors in neuroblastoma in children].
Wieczorek A; Balwierz W
Przegl Lek; 2010; 67(6):393-8. PubMed ID: 21344768
[TBL] [Abstract][Full Text] [Related]
14. Intra-adrenal murine TH-MYCN neuroblastoma tumors grow more aggressive and exhibit a distinct tumor microenvironment relative to their subcutaneous equivalents.
Kroesen M; Brok IC; Reijnen D; van Hout-Kuijer MA; Zeelenberg IS; Den Brok MH; Hoogerbrugge PM; Adema GJ
Cancer Immunol Immunother; 2015 May; 64(5):563-72. PubMed ID: 25687736
[TBL] [Abstract][Full Text] [Related]
15. A signature of 29 immune-related genes pairs to predict prognosis in patients with neuroblastoma.
Song J; Zhao Q; Xu Y; Zhu L
Int Immunopharmacol; 2020 Nov; 88():106994. PubMed ID: 33182060
[TBL] [Abstract][Full Text] [Related]
16. Low Expression of IL-15 and NKT in Tumor Microenvironment Predicts Poor Outcome of MYCN-Non-Amplified Neuroblastoma.
Liao YM; Hung TH; Tung JK; Yu J; Hsu YL; Hung JT; Yu AL
J Pers Med; 2021 Feb; 11(2):. PubMed ID: 33668573
[TBL] [Abstract][Full Text] [Related]
17. MYCN controls an alternative RNA splicing program in high-risk metastatic neuroblastoma.
Zhang S; Wei JS; Li SQ; Badgett TC; Song YK; Agarwal S; Coarfa C; Tolman C; Hurd L; Liao H; He J; Wen X; Liu Z; Thiele CJ; Westermann F; Asgharzadeh S; Seeger RC; Maris JM; Guidry Auvil JM; Smith MA; Kolaczyk ED; Shohet J; Khan J
Cancer Lett; 2016 Feb; 371(2):214-24. PubMed ID: 26683771
[TBL] [Abstract][Full Text] [Related]
18. Identification of an Immune Score-Based Gene Panel with Prognostic Power for Oral Squamous Cell Carcinoma.
Huang SN; Li GS; Zhou XG; Chen XY; Yao YX; Zhang XG; Liang Y; Li MX; Chen G; Huang ZG; Dang YW; Li J; Li P; Tang XZ; Rong MH
Med Sci Monit; 2020 Jun; 26():e922854. PubMed ID: 32529991
[TBL] [Abstract][Full Text] [Related]
19. High anaplastic lymphoma kinase immunohistochemical staining in neuroblastoma and ganglioneuroblastoma is an independent predictor of poor outcome.
Duijkers FAM; Gaal J; Meijerink JPP; Admiraal P; Pieters R; de Krijger RR; van Noesel MM
Am J Pathol; 2012 Mar; 180(3):1223-1231. PubMed ID: 22203052
[TBL] [Abstract][Full Text] [Related]
20. Identification of an Autophagy-Related Risk Signature Correlates With Immunophenotype and Predicts Immune Checkpoint Blockade Efficacy of Neuroblastoma.
Kang W; Hu J; Zhao Q; Song F
Front Cell Dev Biol; 2021; 9():731380. PubMed ID: 34746127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
